Alector Inc logo

ALEC - Alector Inc Share Price

$22.64 0.7  3.0%

Last Trade - 4:41pm

Sector
Healthcare
Size
Mid Cap
Market Cap £1.16bn
Enterprise Value £869.3m
Revenue £18.7m
Position in Universe 2118th / 6416
Bullish
Bearish
Unlock ALEC Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ALEC Revenue Unlock ALEC Revenue

Net Income

ALEC Net Income Unlock ALEC Revenue

Normalised EPS

ALEC Normalised EPS Unlock ALEC Revenue

PE Ratio Range

ALEC PE Ratio Range Unlock ALEC Revenue

Dividend Yield Range

ALEC Dividend Yield Range Unlock ALEC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ALEC EPS Forecasts Unlock ALEC Revenue
Profile Summary

Alector, Inc. is a clinical-stage biopharmaceutical company focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. The Company's platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system. Its platform focuses on target selection, biomarker selection and patient selection. Its product portfolio includes AL001, AL101, Al002 and AL003. Its AL001 targets frontotemporal dementia carrying a progranulin (FTD-GRN).

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated September 19, 2017
Public Since February 7, 2019
No. of Shareholders: 104
No. of Employees: 109
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 68,923,730
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ALEC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ALEC
Upcoming Events for ALEC
Similar to ALEC
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.